Glenview Trust Co Raises Stock Position in IDEXX Laboratories, Inc. $IDXX

Glenview Trust Co lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,729 shares of the company’s stock after buying an additional 2,312 shares during the period. Glenview Trust Co’s holdings in IDEXX Laboratories were worth $26,021,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Blalock Williams LLC purchased a new position in IDEXX Laboratories during the 3rd quarter worth $590,000. New York State Common Retirement Fund boosted its holdings in IDEXX Laboratories by 6.8% in the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after acquiring an additional 3,820 shares in the last quarter. Arkadios Wealth Advisors purchased a new stake in shares of IDEXX Laboratories during the second quarter worth about $405,000. Mediolanum International Funds Ltd increased its holdings in shares of IDEXX Laboratories by 14.5% during the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after acquiring an additional 4,909 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after purchasing an additional 187,967 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $629.35 on Tuesday. The business’s 50-day moving average is $683.44 and its two-hundred day moving average is $669.02. The company has a market capitalization of $50.25 billion, a P/E ratio of 48.15, a P/E/G ratio of 3.83 and a beta of 1.67. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 11,345 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.98% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research analyst reports. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. BTIG Research reduced their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.